2025-06-30 · Hong Kong IPO in 2025 (historical) · Approximately HKD 428.77 million in net proceeds ↗
The annual report specifies approximately HK$428.77m in net proceeds, not gross offering proceeds. No claim is made that no subsequent refinancing occurred.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY IFRS / consolidated
570,087,000
217,371,000 Profit/(loss) attributable to owners of the parent
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
Source financials use CNY thousands, multiplied by 1000 to show CNY. Non-IFRS net income is not directly equivalent to the A-share measure excluding nonrecurring items.
2026H1 · Reporting notes
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
Source financials use CNY thousands, multiplied by 1000 to show CNY. Non-IFRS net income is not directly equivalent to the A-share measure excluding nonrecurring items.
Unaudited. Hong Kong interim reports and A-share nine-month reports cover different periods.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The HKEX 2025 annual report confirms integrated synthetic peptide and oligonucleotide CRDMO. Listed on 2025-06-30.
The full 2025 annual report and 2026 interim report have been obtained.
Program / service
Target / indication
Representative stage
Evidence & scope
CRO/CDMO and research service capabilities
Services / platform
Evidence of services, not clinical data for a drug candidate
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
A service platform does not have the clinical stage of a proprietary drug candidate. Order quality, customer concentration, and capacity utilization require further diligence.
